Sacral Neuromodulation for Male Overactive Bladder (MOAB)

Clinicaltrials.gov ID: NCT06511141
db-list-check Status RECRUITING
b-loader Phase NA
b-people Age ≥ 18 Years
b-bullseye-arrow Enrollments 150

Conditions

Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer, Prostatectomy, Urinary Frequency

Summary

To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.

Detailed Description

To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients who have a prior history of radical prostatectomy or radiation for prostate cancer or who have a history of cytoreductive surgical intervention for benign prostatic hyperplasia (BPH).

Locations

12 locations Found with status Recruiting

Status

  • RECRUITING

Contact Person

  • Alisha Hitt

Study Director

  • Karen Noblett, MD

Status

  • RECRUITING

Contact Person

  • Pam Manley

Study Director

  • Karen Noblett, MD

Status

  • RECRUITING

Contact Person

  • Annette West

Study Director

  • Karen Noblett, MD

Status

  • RECRUITING

Contact Person

  • Vivian Cabral Perez

Study Director

  • Karen Noblett, MD

Status

  • RECRUITING

Contact Person

  • Nicolle Acuna

Study Director

  • Karen Noblett, MD

Status

  • RECRUITING

Contact Person

  • Jaya Mishra, PhD

Study Director

  • Karen Noblett, MD

Status

  • RECRUITING

Contact Person

  • Sherry Stephens

Study Director

  • Karen Noblett, MD

Status

  • RECRUITING

Contact Person

  • Angie Kostreba

Study Director

  • Karen Noblett, MD

Status

  • RECRUITING

Contact Person

  • Lydia Beard

Study Director

  • Karen Noblett, MD

Status

  • RECRUITING

Contact Person

  • Kason Ladd

Study Director

  • Karen Noblett, MD

Status

  • RECRUITING

Contact Person

  • Melissa Howell

Study Director

  • Karen Noblett, MD

Status

  • RECRUITING

Contact Person

  • Mariam Shittu

Study Director

  • Karen Noblett, MD

Eligibility Criteria

Key Inclusion Criteria:

1. Participants aged ≥ 18 years at the time of enrollment
2. Able to complete bladder diaries and patient questionnaires
3. Primary diagnosis of OAB (urinary urgency incontinence (UUI) or urinary frequency (UF)).
4. Willing and capable to provide written informed consent and agrees to comply with specified evaluations at clinical investigational sites and attend all follow-up assessments for up to 1 year

Key Exclusion Criteria:

1. Any patient that is not a suitable candidate per investigator discretion
2. Recent prostate therapy or procedure within the last 6 months at the time of enrollment
3. Any neurological condition that could interfere with normal bladder function, including stroke, epilepsy, multiple sclerosis, Parkinson's disease, clinically significant peripheral neuropathy, or spinal cord injury (e.g., paraplegia)
4. Previously implanted with a sacral neuromodulation device, including inactive SNM devices
5. Any prior treatment with an Implantable Tibial Nerve Stimulation (ITNS)
6. Percutaneous Tibial Nerve Stimulation (PTNS) within the last 3 months at the time of enrollment
7. Underwent an external trial with any sacral neuromodulation device and was deemed a non-responder by a physician
8. Any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound evaluation of study objectives at the Investigator's discretion.
9. Uncontrolled diabetes
10. Known allergic reactions to components of the Axonics SNM System, including titanium, zirconia, polyurethane, epoxy, or silicone

Study Plan

Post-prostatectomy

OTHER

History of radical prostatectomy for cancer treatment at least 6 months prior to enrollment

  • DEVICE:

    Axonics SNM System

    Description:

    To assess clinical outcomes of the Axonics SNM System in the male OAB population.

Radiation

OTHER

History of radiation for cancer treatment at least 6 months prior to enrollment

  • DEVICE:

    Axonics SNM System

    Description:

    To assess clinical outcomes of the Axonics SNM System in the male OAB population.

Benign Prostatic Hyperplasia (BPH)

OTHER

History of cytoreductive BPH surgery at least 6 months prior to enrollment

  • DEVICE:

    Axonics SNM System

    Description:

    To assess clinical outcomes of the Axonics SNM System in the male OAB population.

Outcome Measures

Primary Outcome Measures

Adverse event reporting (Safety)

Time Frame: 6 months, 1 year

Performance/Effectiveness - Reduction in UUI or UF episodes

Time Frame: 6 months, 1 year

Secondary Outcome Measures

Performance/Effectiveness - Improvement in Quality of Life scoring

Time Frame: 6 months, 1 year

Timeline

  • Last Updated
    August 11, 2025
  • Start Date
    July 19, 2024
  • Today
    October 19, 2025
  • Completion Date ( Estimated )
    December 1, 2027

Similar Trials

light-list-check RECRUITING light-blue-people ≥ 18 Years
light-list-check RECRUITING light-blue-people ≥ 70 Years
light-list-check RECRUITING light-blue-people ≥ 45 Years